Hemostemix to Showcase at Life Science Investor Meeting
In a significant development for the medical field, Hemostemix Inc., a leading autologous stem cell therapy company, has announced that it can now legally offer its patented therapy, ACP-01, to no-option patients in Florida. This decision comes following the passage of Florida Senate Bill 1768 (SB 1768).
Thomas Smeenk, President, CEO, and Co-Founder of Hemostemix Inc., will present at the Life Science Investor Forum on September 18, 2025, at 12:00 p.m. ET. Interested parties can access the presentation at this link.
ACP-01 has shown promising results in treating various cardiovascular diseases, including peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The therapy has demonstrated efficacy in treating no-option patients with severe angina and heart failure, with 0% mortality, cessation of pain, and wound healing in 83% of patients followed for up to 4.5 years, as reported by UBC and U of T at the 41st meeting of vascular surgeons.
Thomas Smeenk, in a recent statement, emphasised the significance of ACP-01, stating, "ACP-01 is not science fiction but science fact, with a strong body of peer-reviewed evidence." Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications.
The Life Science Investor Forum is an interactive online event for institutional and individual investors. For more information about Hemostemix Inc., please contact Thomas Smeenk at [email protected] or 905-580-4170.
It is important to note that the forward-looking information in this news release reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. Hemostemix's forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information.
Hemostemix Inc., founded in 2003, has completed 498 safe treatments to date. For more details about the company and its therapies, visit their website. A recent peer-reviewed article in Cells (June 29, 2025) also provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance.
Read also:
- Eight strategies for promoting restful slumber in individuals with hypertrophic cardiomyopathy
- Exploring the Strength of Minimally Digestible Diets: A Roadmap to Gastrointestinal Healing
- Secondhand Smoke: Understanding its Nature, Impact on Health, and Additional Facts
- Overseeing and addressing seizure-induced high blood pressure complications in pregnancy, known as eclampsia
